- Rapport Therapeutics announced **impressive Phase 2 data** for **RAP-219** in treatment-resistant focal epilepsy, demonstrating a **78% median reduction in clinical seizures** and a **24% seizure freedom rate**.  **[2012593_2146249_0]** 
- The trial showcased a **differentiated tolerability profile** with a **10% discontinuation rate**, which is considered very low for proof-of-concept studies in this patient population, and no observed aggression or rage.  **[2012593_2146249_3]** 
- Management believes RAP-219 has a **multi-billion dollar market opportunity**, potentially exceeding initial peak sales estimates of $1.5 billion due to its profile and anticipated broad adoption by general neurologists and internists.  **[2012593_2146249_0]** **[2012593_2146249_5]** 
- The company is funded into the **second half of 2029**, enabling the initiation of **two parallel Phase 3 studies in Q3 2026** for focal onset seizures, as well as advancing a long-acting injectable and a bipolar mania trial.  **[2012593_2146249_1]** **[2012593_2146249_7]**

Rapport Therapeutics (RAPP)